Ascendis Pharma A/S (ASND) stock
ASNDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 7/30
$270.33−0.86 (-0.32%)
Close on Nov 18, 2026Market cap $16.75BP/E 22.2Yield –
Ascendis Pharma A/S shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Ascendis Pharma A/S's shares outstanding was 68M at Jun 30, 2026. For fiscal 2025 it was 61M, up 4.7% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is 61M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 61M | +4.7% |
| FY2024 | Dec 31, 2024 | 58M | +2.9% |
| FY2023 | Dec 31, 2023 | 56M | +0.4% |
| FY2022 | Dec 31, 2022 | 56M | +2.4% |
| FY2021 | Dec 31, 2021 | 55M | +8.2% |
| FY2020 | Dec 31, 2020 | 51M | +8.8% |
| FY2019 | Dec 31, 2019 | 47M | +13.2% |
| FY2018 | Dec 31, 2018 | 41M | +22.2% |
| FY2017 | Dec 31, 2017 | 34M | +26.6% |
| FY2016 | Dec 31, 2016 | 27M | +11.8% |
| FY2015 | Dec 31, 2015 | 24M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 68M | +6.9% |
| Q1 FY2026 | Mar 31, 2026 | 65M | +7.5% |
| Q4 FY2025 | Dec 31, 2025 | 61M | +2.3% |
| Q3 FY2025 | Sep 30, 2025 | 61M | +5.6% |
| Q2 FY2025 | Jun 30, 2025 | 64M | +5.1% |
| Q1 FY2025 | Mar 31, 2025 | 60M | +5.5% |
| Q4 FY2024 | Dec 31, 2024 | 60M | +5.7% |
| Q3 FY2024 | Sep 30, 2024 | 58M | +2.2% |
| Q2 FY2024 | Jun 30, 2024 | 61M | +8.2% |
| Q1 FY2024 | Mar 31, 2024 | 57M | +1.4% |
| Q4 FY2023 | Dec 31, 2023 | 57M | +1.1% |
| Q3 FY2023 | Sep 30, 2023 | 56M | +0.8% |
| Q2 FY2023 | Jun 30, 2023 | 56M | +0.7% |
| Q1 FY2023 | Mar 31, 2023 | 56M | -1.1% |
| Q4 FY2022 | Dec 31, 2022 | 56M | -1.6% |
| Q3 FY2022 | Sep 30, 2022 | 56M | +2.2% |
| Q2 FY2022 | Jun 30, 2022 | 56M | +3.6% |
| Q1 FY2022 | Mar 31, 2022 | 57M | +5.5% |
| Q4 FY2021 | Dec 31, 2021 | 57M | +6.2% |
| Q3 FY2021 | Sep 30, 2021 | 55M | +3.7% |
| Q2 FY2021 | Jun 30, 2021 | 54M | +11.7% |
| Q1 FY2021 | Mar 31, 2021 | 54M | +12.0% |
| Q4 FY2020 | Dec 31, 2020 | 54M | +11.9% |
| Q3 FY2020 | Sep 30, 2020 | 53M | +10.8% |
| Q2 FY2020 | Jun 30, 2020 | 48M | +2.2% |
| Q1 FY2020 | Mar 31, 2020 | 48M | +10.6% |
| Q4 FY2019 | Dec 31, 2019 | 48M | +13.7% |
| Q3 FY2019 | Sep 30, 2019 | 48M | +13.6% |
| Q2 FY2019 | Jun 30, 2019 | 47M | +13.3% |
| Q1 FY2019 | Mar 31, 2019 | 43M | +12.1% |
| Q4 FY2018 | Dec 31, 2018 | 42M | +13.8% |
| Q3 FY2018 | Sep 30, 2018 | 42M | +28.5% |
| Q2 FY2018 | Jun 30, 2018 | 42M | +28.1% |
| Q1 FY2018 | Mar 31, 2018 | 39M | +19.3% |
| Q4 FY2017 | Dec 31, 2017 | 37M | – |
| Q3 FY2017 | Sep 30, 2017 | 33M | – |
| Q2 FY2017 | Jun 30, 2017 | 33M | – |
| Q1 FY2017 | Mar 31, 2017 | 32M | – |
See a number that looks wrong?